Global private equity and venture capital news and research

Venture capital-backed Dicerna prices IPO at $11 to $13 per share

22 Jan 2014

dnaVenture capital-backed RNA interference-based therapeutics developer Dicerna Pharmaceuticals has priced its IPO at $11 to $13 per share.

Jefferies, Leerink Partners, Stifel and Baird are acting as underwriters for the IPO, according to a document filed with the US Securities and Exchange Commission.

Dicerna will trade on the Nasdaq exchange under the symbol DRNA, the filing showed.

The company is backed by RA Capital, Brookside Capital, Deerfield, Omega Funds, Abingworth Management, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One.

Last August Dicerna raised $60m in an oversubscribed Series C round.

Copyright © 2014 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016